RenovoRx: Boston Scientific sells 544K shares

Boston Scientific reports no beneficial ownership in RenovoRx as of September 30, 2026, and designates this as its final amendment.

Available on EDGAR 11/06/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

RenovoRx, Inc. (RNXT) is the issuer in an ownership amendment reporting that Boston Scientific Corporation sold 543,971 shares of its common stock in August 2026. As of September 30, 2026, Boston Scientific beneficially owned 0 shares, or 0% of the class, and identified the amendment as its final amendment and exit filing.

Key Figures

Common shares sold: 543,971 shares Shares beneficially owned: 0 shares Percent of class beneficially owned: 0%

3 metrics

Common shares sold 543,971 shares Sold in August 2026

Shares beneficially owned 0 shares As of September 30, 2026

Percent of class beneficially owned 0% As of September 30, 2026

Key Terms

beneficial owner, Sole power to vote, Shared power to dispose

3 terms

beneficial owner regulatory

"ceased to be the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole power to vote regulatory

"Sole power to vote or to direct the vote"

Shared power to dispose regulatory

"Shared power to dispose or to direct the disposition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RNXT shares did Boston Scientific sell?

Boston Scientific Corporation reports selling 543,971 shares of RenovoRx common stock in August 2026.

How many RNXT shares did Boston Scientific own after the sale?

As of September 30, 2026, Boston Scientific Corporation reported beneficial ownership of 0 shares, or 0% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

RenovoRx, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

75989R107

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 75989R107

1

Names of Reporting Persons

BOSTON SCIENTIFIC CORP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: RenovoRx, Inc.
(b)	Address of issuer's principal executive offices: 2570 West El Camino Real, Suite 640, Mountain View, CA 94040
Item 2.
(a)	Name of person filing: Boston Scientific Corporation
(b)	Address or principal business office or, if none, residence: 300 Boston Scientific Way, Marlborough, MA 01752
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 75989R107
Item 4.	Ownership
(a)	Amount beneficially owned: 0 This Amendment No. 1 (this "Amendment") amends in its entirety the statement on Schedule 13G originally filed on February 10, 2022 by Boston Scientific Corporation (the "Reporting Person"). In August 2026, the Reporting Person sold 543,971 shares of common stock, $0.0001 par value, of RenovoRx, Inc. (the "Issuer"). This Amendment is being filed to disclose that as of September 30, 2026, the Reporting Person has ceased to be the beneficial owner of more than 5% of the outstanding shares of common stock of the Issuer. This Amendment is the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Person.
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BOSTON SCIENTIFIC CORP

Signature:	/s/ Susan Thompson
Name/Title:	Vice President, Chief Corporate Counsel and Assistant Secretary
Date:	11/06/2026